WO2009092892A3 - Nouvelle composition pour traiter les effets secondaires des traitements anticancereux - Google Patents

Nouvelle composition pour traiter les effets secondaires des traitements anticancereux Download PDF

Info

Publication number
WO2009092892A3
WO2009092892A3 PCT/FR2008/001528 FR2008001528W WO2009092892A3 WO 2009092892 A3 WO2009092892 A3 WO 2009092892A3 FR 2008001528 W FR2008001528 W FR 2008001528W WO 2009092892 A3 WO2009092892 A3 WO 2009092892A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
side effects
anticancer treatments
novel composition
anticancer
Prior art date
Application number
PCT/FR2008/001528
Other languages
English (en)
Other versions
WO2009092892A2 (fr
Inventor
Rebecca Pruss
Thierry Bordet
Jean-Louis Abitbol
Antoine Beret
Original Assignee
Trophos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophos filed Critical Trophos
Priority to MX2010004859A priority Critical patent/MX2010004859A/es
Priority to CA2704128A priority patent/CA2704128A1/fr
Priority to NZ584849A priority patent/NZ584849A/en
Priority to EP08871617A priority patent/EP2214789A2/fr
Priority to RU2010121882/15A priority patent/RU2485956C2/ru
Priority to AU2008348717A priority patent/AU2008348717B2/en
Priority to JP2010530513A priority patent/JP2011502112A/ja
Priority to US12/740,478 priority patent/US20100310674A1/en
Publication of WO2009092892A2 publication Critical patent/WO2009092892A2/fr
Publication of WO2009092892A3 publication Critical patent/WO2009092892A3/fr
Priority to ZA2010/02576A priority patent/ZA201002576B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouvelles compositions, particulièrement pharmaceutiques, comprenant au moins, comme actifs, moins un agent cytotoxigue et d'au moins un dérivé d'oxime de cholest-4-èn-3-one pour traiter les effets secondaires des traitements anticancéreux.
PCT/FR2008/001528 2007-10-30 2008-10-30 Nouvelle composition pour traiter les effets secondaires des traitements anticancereux WO2009092892A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2010004859A MX2010004859A (es) 2007-10-30 2008-10-30 Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
CA2704128A CA2704128A1 (fr) 2007-10-30 2008-10-30 Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
NZ584849A NZ584849A (en) 2007-10-30 2008-10-30 Novel composition for treating the side effects of anticancer treatments
EP08871617A EP2214789A2 (fr) 2007-10-30 2008-10-30 Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
RU2010121882/15A RU2485956C2 (ru) 2007-10-30 2008-10-30 Новая композиция для лечения побочных эффектов противораковой терапии
AU2008348717A AU2008348717B2 (en) 2007-10-30 2008-10-30 Novel composition for treating the side effects of anticancer treatments
JP2010530513A JP2011502112A (ja) 2007-10-30 2008-10-30 抗ガン治療の副作用を治療するための新規組成物
US12/740,478 US20100310674A1 (en) 2007-10-30 2008-10-30 Novel composition for treating the side effects of anticancer treatments
ZA2010/02576A ZA201002576B (en) 2007-10-30 2010-04-13 Novel composition for treating the side effects of anticancer treatments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0707625 2007-10-30
FR0707625 2007-10-30

Publications (2)

Publication Number Publication Date
WO2009092892A2 WO2009092892A2 (fr) 2009-07-30
WO2009092892A3 true WO2009092892A3 (fr) 2009-09-17

Family

ID=40791126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001528 WO2009092892A2 (fr) 2007-10-30 2008-10-30 Nouvelle composition pour traiter les effets secondaires des traitements anticancereux

Country Status (10)

Country Link
US (1) US20100310674A1 (fr)
EP (1) EP2214789A2 (fr)
JP (1) JP2011502112A (fr)
AU (1) AU2008348717B2 (fr)
CA (1) CA2704128A1 (fr)
MX (1) MX2010004859A (fr)
NZ (1) NZ584849A (fr)
RU (1) RU2485956C2 (fr)
WO (1) WO2009092892A2 (fr)
ZA (1) ZA201002576B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874923B1 (fr) * 2004-09-07 2006-10-27 Trophos Sa Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
FR2919180B1 (fr) * 2007-07-25 2009-11-27 Trophos Utilisation d'au moins un derive oxime de la cholest-4-en-3-one comme antioxydants
CN111789956B (zh) * 2011-04-27 2023-02-17 耶鲁大学 用于抑制化疗引起副作用的药物治疗、筛选技术和试剂盒
FR2979239A1 (fr) 2011-08-25 2013-03-01 Trophos Liposome comprenant au moins un derive de cholesterol

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186347A (ja) * 1991-07-26 1993-07-27 Kyoto Kenko Kagaku Kenkyusho:Kk 細胞障害性制癌剤の副作用軽減および制癌作用増強剤
WO1998058676A1 (fr) * 1997-06-23 1998-12-30 N-Gene Research Laboratories Inc. Composition pharmaceutique presentant une activite antitumorale amelioree et/ou des effets secondaires reduits contenant un agent antitumoral et un derive d'acide hydroximique
WO2004043454A1 (fr) * 2002-11-13 2004-05-27 Sigma-Tau Industrie Farmaceutiche Riunite Spa Acetyle-l-carnitine pour la prevention et/ou le traitement de neuropathies peripheriques induites par des agents anticancereux
WO2004082581A2 (fr) * 2003-03-11 2004-09-30 Trophos Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2007080270A2 (fr) * 2005-12-20 2007-07-19 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2898272B1 (fr) * 2006-03-09 2008-07-04 Trophos Sa Utilisation de derives du 3,5-seco-4-nor-cholestrane pour l'obtention d'un medicament cytoprotecteur
FR2899108B1 (fr) * 2006-03-31 2012-02-03 Trophos Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186347A (ja) * 1991-07-26 1993-07-27 Kyoto Kenko Kagaku Kenkyusho:Kk 細胞障害性制癌剤の副作用軽減および制癌作用増強剤
WO1998058676A1 (fr) * 1997-06-23 1998-12-30 N-Gene Research Laboratories Inc. Composition pharmaceutique presentant une activite antitumorale amelioree et/ou des effets secondaires reduits contenant un agent antitumoral et un derive d'acide hydroximique
WO2004043454A1 (fr) * 2002-11-13 2004-05-27 Sigma-Tau Industrie Farmaceutiche Riunite Spa Acetyle-l-carnitine pour la prevention et/ou le traitement de neuropathies peripheriques induites par des agents anticancereux
WO2004082581A2 (fr) * 2003-03-11 2004-09-30 Trophos Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2007080270A2 (fr) * 2005-12-20 2007-07-19 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BORDET THIERRY ET AL: "Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 326, no. 2, 1 August 2008 (2008-08-01), pages 623 - 632, XP009119473, ISSN: 0022-3565, [retrieved on 20080520] *
LONN U ET AL: "Cytotoxicity, calmodulin and DNA lesions in cells treated with streptozotocin", BIOCHEMICAL PHARMACOLOGY, vol. 37, no. 18, 15 September 1988 (1988-09-15), pages 3441 - 3446, XP023758171, ISSN: 0006-2952, [retrieved on 19880915] *
PRUSS ET AL: "Abs163 - TRO19622 targets mitochondria and reverses pain in animal models of neuropathic pain", EUROPEAN JOURNAL OF PAIN, vol. 11, no. S1, 11 May 2007 (2007-05-11) - June 2007 (2007-06-01), &the Second International Congress on Neuropathic Pain (NeuPSIG) Berlin, Germany, June 7-10,2007, pages S70 - S71, XP022076127, ISSN: 1090-3801 *
PRUSS REBECCA M ET AL: "TRO19622, a Mitochondrial Targeted Neuroprotective Compound, Prevents and Reverses Paclitaxel-Induced Painful Peripheral Neuropathy", NEUROLOGY, vol. 72, no. 11, Suppl. 3, March 2009 (2009-03-01), & 61ST ANNUAL MEETING OF AMERICAN-ACADEMY-OF-NEUROLOGY; SEATTLE, WA, USA; APRIL 28 -29, 2009, pages A211, XP009119508, ISSN: 0028-3878 *
TRESKES M ET AL: "WR2721 AS A MODULATOR OF CISPLATIN- AND CARBOPLATIN-INDUCED SIDE EFFECTS IN COMPARISON WITH OTHER CHEMOPROTECTIVE AGENTS: A MOLECULAR APPROACH", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 33, no. 2, 1 November 1993 (1993-11-01), pages 93 - 106, XP002053093, ISSN: 0344-5704 *
VERSCHUEREN A ET AL: "ABS C78 - TRO19622 is well tolerated and target plasma concentrations are obtained at doses 250/500 mg once a day in a one month als phase 1B, add-on to Riluzole, clinical study", AMYOTROPHIC LATERAL SCLEROSIS, vol. 8, no. S1, 3 December 2007 (2007-12-03), &18th International Symposium on ALS/MND, Session 9B, 1-3.12.2007, Toronto, Canada, pages 59 - 60, XP009119493, ISSN: 1748-2968 *
VITALI G ET AL: "SYMPTOMATIC AND NEUROPHYSIOLIGICAL RESPONSE OF PACLITAXEL AND/OR CISPLATIN NEUROPATHY TO ORAL ACETYL-L-CARNITINE (ALCAR)", ANNALS OF ONCOLOGY,, vol. 13, no. SUPPL. 05, 1 January 2002 (2002-01-01), pages 179X - ABS 659P, XP009027696, ISSN: 0923-7534 *

Also Published As

Publication number Publication date
AU2008348717A1 (en) 2009-07-30
CA2704128A1 (fr) 2009-07-30
WO2009092892A2 (fr) 2009-07-30
AU2008348717B2 (en) 2013-09-19
EP2214789A2 (fr) 2010-08-11
ZA201002576B (en) 2011-03-30
JP2011502112A (ja) 2011-01-20
MX2010004859A (es) 2010-06-21
US20100310674A1 (en) 2010-12-09
NZ584849A (en) 2012-04-27
RU2485956C2 (ru) 2013-06-27
RU2010121882A (ru) 2011-12-10

Similar Documents

Publication Publication Date Title
WO2008097640A3 (fr) Composés à base de triazole modulant l'activité de hsp90
EP2586778A3 (fr) Dérivés de pyridazinone utiles en tant qu'inhibiteurs de synthase de glucane
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007064931A3 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
WO2007066150A3 (fr) Administration de principes actifs par voie transdermique pour l'obtention d'un effet systemique
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2008021368A3 (fr) Compositions et méthodes de neuroprotection
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2012103038A3 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
WO2008116135A3 (fr) Formulations topiques ayant une biodisponibilité amplifiée
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2009147205A3 (fr) Mélanges fongicides synergiques
WO2012065958A9 (fr) Procédé de traitement d'une néphropathie induite par les produits de contraste
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2008070670A3 (fr) Formulations de topiramate à libération immédiate améliorées
WO2008011173A3 (fr) Amélioration des concentrations ou de l'activité de l'arginase
WO2009090237A3 (fr) Dérivés fongicides d'hydroximoyl-tétrazoles
WO2007028022A3 (fr) Nouveaux composes servant de modulateurs de p2x7 et leurs utilisations
WO2007121088A3 (fr) Combinaisons d'agents thérapeutiques pour traiter un cancer
WO2011087548A3 (fr) Compositions thérapeutiques et méthodes d'administration ciblée de principes actifs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08871617

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2008871617

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008871617

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 584849

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2410/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010530513

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2704128

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004859

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010121882

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008348717

Country of ref document: AU

Date of ref document: 20081030

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12740478

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0818747

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100429